GlassScriptPhysician profile
Scott Zashin
NPI 1255364048
$68,770.62
in general payments reported to CMS, 2019-2025
24 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $14K · 2021: $7,447 · 2022: $18K · 2023: $4,308 · 2024: $596 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,200 · Food and Beverage: $1,869 · Travel and Lodging: $316 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,200.00 |
| Food and Beverage | $1,868.96 |
| Travel and Lodging | $315.74 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,866.99 | 2019-2025 | Rinvoq, Humira |
| Amgen INC. | $22,516.00 | 2019-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $6,167.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $4,245.21 | 2019-2025 | |
| Horizon Therapeutics Plc | $2,838.30 | 2019-2021 | |
| Janssen Biotech, INC. | $396.31 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Genentech USA, INC. | $358.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $349.45 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.85 | 2023-2025 | Cyltezo, Ofev |
| Ucb, INC. | $180.40 | 2020-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $155.82 | 2019-2024 | Benlysta |
| Lilly USA, LLC | $111.97 | 2019-2024 | Taltz |
| Pfizer INC. | $65.94 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $62.27 | 2023 | Acthar |
| Medexus Pharma, INC. | $57.33 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.36 | 2019 | |
| Ani Pharmaceuticals, INC. | $40.43 | 2024-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $32.16 | 2023 | Idacio |
| Ultragenyx Pharmaceutical INC. | $22.60 | 2023 | |
| Organon LLC | $18.61 | 2023 | Renflexis, Hadlima |
| Sobi, INC | $17.15 | 2020 | |
| Kyowa Kirin, INC. | $17.08 | 2025 | |
| Octapharma USA, INC. | $13.62 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Zashin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.